Well I asked my cousin about this study, and his responses were:
"There's a reason we don't do much clinical work in Brazil. On the good side, finally, someone did a randomized trial so that the baseline severity was well matched. But it was an open label study, which means both the doctor and patient know what drug they were on. Here are the two that disqualify the study: 1) 50% of patients in all groups were on HQC and/or AZT within 24 hours of starting the study. Think about that, 50% of patients that you randomize were on the drugs before you randomize them. 2) They allowed up to 14 days of symptoms prior to enrollment. The Yale guy and everyone else told us before march that we needed to start treatment within 4 days. This has been further qualified to 24-48.
This is where the Yale doctor is exactly right, many people do/did not want to study the potential of a therapeutic fairly. When you do undisciplined studies and have a bias, it's junk science. But also think about my first point, in second world countries 50% of patients with symptoms are getting these drugs and Americans are not, in a large part because people made it political. The Yale doctor did a nice job of explaining the flaws in many of the early studies in many of the early studies, but did not cover this one. He also mentioned a large share of the patients in developed and developing nations started receiving HQC with AT or doxycycline in MArch. I can only imagine how many tens of thousands of lives could have been spared in the US, if patients and doctors were not deterred from prescribing them. Many of those front line doctors took either or both drugs for months in the hopes they would be protective or prophylactic.
The Yale doctor is right, everyone with a positive COVID test and symptoms and/or risk factors should be offered HQC. If they progress, they should get IV remdesivir.